Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

U.S. Payer and Prescriber Attitudes Toward Novel Oral, Topical, and Biologic Emerging Agents in the Psoriasis Market: Implications for Market Access 11/14/2012 \| published by: Decision Resources ... Biotech/Janssen-Cilag). Further intensifying the future competitive landscape, two agents in late-stage trials for psoriasis offer the advantage of oral formulation: Pfizer’s Jak inhibitor tofacitinib and Celgene’s phosphodiesterase-4 (PDE-4) inhibitor apremilast. Efficacious IL-17 inhibitors are also ... \| read more...	$10,000.00
TreatmentTrends®: Rheumatoid Arthritis (EU) 2012 11/14/2012 \| published by: Decision Resources ... agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, and sales force performance. TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight ... \| read more...	$15,000.00
Atrial Fibrillation in China 11/13/2012 \| published by: Decision Resources ... well as its main complication: stroke. Furthermore, the opportunity for novel therapies that reduce stroke and agents that can maintain regular heart rhythm is expanding because of an aging population and growing awareness of the ... \| read more...	$15,000.00
Migraine 11/12/2012 \| published by: Decision Resources ... emerging therapies, and, coupled with increases in the acute and prophylactic drug-treated populations, the migraine market will grow from $3.3 billion in 2011 to $5.8 billion in 2021. Despite the widespread genericization of the acute ... \| read more...	$15,000.00
LaunchTrends®: Xalkori (Wave 3) 2012 11/9/2012 \| published by: Decision Resources ... of Xalkori at launch (within 1 month of availability) 6 months and 1 year following the August 2011 launch. LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products from launch ... \| read more...	$15,000.00
TreatmentTrends®: Age-Related Macular Degeneration (EU) 2012 11/9/2012 \| published by: Decision Resources ... explored from the perspective of retinal specialists and general ophthalmologists. TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected ... \| read more...	$15,000.00
TreatmentTrends®: Pneumonia (US) 2012 11/9/2012 \| published by: Decision Resources ... practices for the treatment of pneumonia due to emerging and clinically-important pathogens, including MRSA and Pseudomonas aeruginosa. TreatmentTrends® is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice patterns, ... \| read more...	$15,000.00
How Will U.S. Payers and Prescribers Determine the Success of New Biologics and Oral Entrants and Currently Marketed Biologics in Psoriatic Arthritis and Axial Spondyloarthritis? 11/9/2012 \| published by: Decision Resources ... of 100 rheumatologists and 25 pharmacy directors at MCOs that offer both commercial health insurance and Medicare plans. PsA and SpA—which refers to a disease continuum including both undifferentiated (nonradiographic) axial SpA and ankylosing spondylitis ... \| read more...	$10,000.00
Oncology Patient Flow Model: Head and Neck Cancer 11/9/2012 \| published by: Decision Resources ... a 20 year forecast period in a data rich, graphical and interactive environment with Pharmacor Patient Flow Models. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
Community-Acquired Bacterial Pneumonia 11/9/2012 \| published by: Decision Resources ... the number of patients with severe disease, creating an important need for new therapies that are active against key drug-resistant pathogens and that can demonstrate efficacy in the moderate to severe CABP population. Although the ... \| read more...	$15,000.00
TreatmentTrends®: Hepatitis C (US) (Wave 2) 2012 11/7/2012 \| published by: Decision Resources ... share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs. In addition, assessment of the impact of newer agents such as ... \| read more...	$15,000.00
How Will Payer and Prescriber Attitudes Toward Emerging LABA/LAMA and LABA/ICS Fixed-Dose Combinations Shape the COPD Markets in the EU5? 11/6/2012 \| published by: Decision Resources ... of delivering two drugs in one inhaler, these FDCs are among the most prescribed drugs for COPD. Physicians also favor Boehringer Ingelheim/Pfizer’s Spiriva (tiotropium), a long-acting muscarinic antagonist (LAMA). However, the European COPD therapy market ... \| read more...	$10,000.00
Multiple Sclerosis 11/6/2012 \| published by: Decision Resources ... broad array of new and promising treatment alternatives, including unique oral and parenteral products, is expected to launch for the treatment of relapsing forms of MS, driving further transformation and fragmentation of the MS market. ... \| read more...	$15,000.00
Atrial Fibrillation 11/6/2012 \| published by: Decision Resources ... new agents that can prevent stroke in AF patients and restore a regular heart rhythm is expanding owing to the aging of the population and the limitations of existing agents. New drugs in development stand ... \| read more...	$15,000.00
PCPs in an IFN-Free World: How Will the Availability of Safer and More Effective Oral Therapies Impact the Role of PCPs in Treating HCV Patients? 11/5/2012 \| published by: Decision Resources ... (telaprevir) or Merck/Roche’s Victrelis (boceprevir). Although these therapies are effective, each of these drug classes comes with significant safety and tolerability issues. Consequently, up to half of the diagnosed patient population is unable or unwilling ... \| read more...	$10,000.00
Special Report: Planning for the Inclusion of Oral-Only Medications in the Dialysis Bundle 2012 11/5/2012 \| published by: Decision Resources ... as separately billable (i.e. profit centers) items but represent a cost to the dialysis center. We have seen changes in the management and treatment strategies in the dialysis market (e.g., a reduced use of ESAs) ... \| read more...	$15,000.00
TreatmentTrends®: Lupus (US) 2012 11/2/2012 \| published by: Decision Resources ... perceptions about attribute importance and product performance; and drivers and barriers to product adoption and usage. Finally, the report will provide a competitive review of the awareness of new products in late stage development. TreatmentTrends ... \| read more...	$15,000.00
ChartTrends®: Rheumatoid Arthritis (EU) 2012 10/31/2012 \| published by: Decision Resources ... what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, concomitant medications, and a host ... \| read more...	$15,000.00
TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU) 2012 10/31/2012 \| published by: Decision Resources ... clinically-important Gram-positive pathogens, such as CA-MRSA, HA-MRSA, VISA, VRSA, and VRE. TreatmentTrends® is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice pat-terns, attitudes and perceptions, unmet needs, and ... \| read more...	$15,000.00
Oncology Patient Flow Model: Prostate Cancer 10/30/2012 \| published by: Decision Resources ... a 20 year forecast period in a data rich, graphical and interactive environment with Pharmacor Patient Flow Models. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
ChartTrends®: Bone and Mineral Metabolism in CKD-ND (US) 2012 10/30/2012 \| published by: Decision Resources ... (CKD) patient records. BioTrends has been covering the US Dialysis and CKD markets since 2004. This will be the seventh wave of the ChartTrends report. ChartTrends® are syndicated reports designed to compare what physicians self-report ... \| read more...	$15,000.00
LaunchTrends®: Yervoy & Zelboraf (Wave 3) 2012 10/29/2012 \| published by: Decision Resources ... Inc.’s Zelboraf. Wave 1 tracks the uptake of Yervoy 6 months post-launch and Zelboraf at launch while subsequent waves will be fielded every 6 months to monitor the competitive dynamics of these therapies. LaunchTrends® are ... \| read more...	$15,000.00
ChartTrends®: Multiple Sclerosis (US) 2012 10/25/2012 \| published by: Decision Resources ... audits are completed by 200+ neurologists who submit between four and seven audits each. Respondents are limited to one patient per disease modifying agent (DMA) brand (Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif and Tysabri). At ... \| read more...	$15,000.00
Innovative R&D and Dealmaking Opportunities: Oncology Biologics: Novel Therapeutic Antibodies, Proteins, and Peptides 10/24/2012 \| published by: Decision Resources ... sales: Roche/Chugai’s Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan/MabThera (rituximab). Developments in the design of MAbs have progressed rapidly, moving from murine-based biologics to humanized and fully human antibodies. More recently, companies have been creating and ... \| read more...	$10,000.00
Physician and Payer Receptivity to Novel Agents in Chronic Non-Neuropathic Pain: What Are the Market Access Levers in the EU5? 10/22/2012 \| published by: Decision Resources ... back pain, fibromyalgia, musculoskeletal pain, postoperative pain, painful diabetic neuropathy, post-herpetic neuralgia, and cancer pain), treatment of refractory pain remains a challenge for physicians and, coupled with the high prevalence of pain, presents significant opportunity ... \| read more...	$10,000.00

< prev 1 2 3 4 5 6 7 8 9 10 next >